H3D is the first and only centre of its kind on the African continent, an integrated drug discovery and development centre with TB, malaria and AMR platforms

Joined October 2020
In #JMedChem, Dziwornu and Mmonwa et al. reveal novel inhibitors of Plasmodium PI4KIIIβ, based on the ATM kinase inhibitor AZD0156, with low propensity for resistance and in vivo efficacy in a humanised mouse #malaria infection model 🐭 @UCTIDM @UCT_news pubs.acs.org/doi/full/10.102…
3
6
287
📣 New book chapter! "Multi-Target Antimalarials as a Strategy to Reduce Resistance Risk", written by Lauren B. Coulson and @Kelly_Chibale and appearing in "Polypharmacology: Strategies for Multi‐Target Drug Discovery" 💊 @UCTIDM @UCT_news onlinelibrary.wiley.com/doi/…
1
7
146
Academic–industry #collaborations are a powerful catalyst for pharmaceutical innovation. Drawing on experiences at H3D, Winks et al. explore the benefits and challenges in the context of #drugdiscovery in this ACS Med. Chem. Lett. Viewpoint 💊 pubs.acs.org/doi/full/10.102…
2
288
Now out in #JMedChem! 💊 We report SARs for sapanisertib, identifying analogues with improved safety profiles and dual inhibitory activities against high-value Plasmodium targets PI4Kβ and PKG; a selected compound achieved an in vivo proof-of-concept 🐭 pubs.acs.org/doi/10.1021/acs…
1
1
11
346
In #JMedChem, we report a spiroindoline series with high sp3 character and potent activity against drug-resistant #malaria parasites. SAR explorations yielded a novel pyridylspiroindoline frontrunner (50) with promise for further optimisation 🔄 @UCTIDM pubs.acs.org/doi/full/10.102…
1
112
Despite the use of mefloquine in malaria prophylaxis and treatment, its metabolism is not completely understood. In our latest publication in #DrugMetabDispos, Cloete et al. identify CYP1A2 as a key enzyme involved in mefloquine metabolism: sciencedirect.com/science/ar…
1
2
147
Identification of novel drug targets is a key component of modern #drugdiscovery 💡 We were part of a team that systematically assessed the P. falciparum genome to identify a list of 27 high-priority antimalarial targets. Read more in npj Drug Discovery! nature.com/articles/s44386-0…
1
8
238
Our latest article, appearing in #FEBSLett, elucidates the molecular basis of inhibition of human angiotensin-1 converting enzyme (ACE), an important target for hypertension and inflammation, by a series of diprolyl-derived compounds: febs.onlinelibrary.wiley.com… 🧬 @UCT_news @UCTIDM
1
1
5
259
Appearing in the European Journal of Medicinal Chemistry, our latest publication by Dziwornu and Attram et al. reports the antischistosomal potential of a new series of compounds derived from the privileged benzimidazole scaffold: doi.org/10.1016/j.ejmech.202… 🌍 @UCT_news @UCTIDM
4
188
🎉 Wrapping Up 2024 with Gratitude and Joy 🎉 As 2024 ends, we reflect on what a wonderfully busy and fulfilling year it has been for everyone @H3D. From all of us @H3D, we wish you a happy and joyous holiday season! Here’s to a bright and inspiring year ahead! ✨
3
1
13
702
Exciting Opportunity: Join @H3D_UCT as a Postdoc Fellow in Medicinal Chemistry @H3D_UCT is looking for talented postdoctoral fellows to contribute to cutting-edge research Closing Date: 10 Jan 2025 #PostDocOpportunity #MedicinalChemistry
12
14
1,769
Recently published in #NatCommun, Naude et al. shine light on how lipoidal uptake of antimalarial compounds influences their asexual blood stage versus transmission-blocking capabilities: nature.com/articles/s41467-0… @UCT_news @UCTIDM 🦟
1
1
155